55 related articles for article (PubMed ID: 16024608)
21. Targeting the acute promyelocytic leukemia-associated fusion proteins PML/RARα and PLZF/RARα with interfering peptides.
Beez S; Demmer P; Puccetti E
PLoS One; 2012; 7(11):e48636. PubMed ID: 23152790
[TBL] [Abstract][Full Text] [Related]
22. Formation of PML/RAR alpha high molecular weight nuclear complexes through the PML coiled-coil region is essential for the PML/RAR alpha-mediated retinoic acid response.
Grignani F; Gelmetti V; Fanelli M; Rogaia D; De Matteis S; Ferrara FF; Bonci D; Grignani F; Nervi C; Pelicci PG
Oncogene; 1999 Nov; 18(46):6313-21. PubMed ID: 10597230
[TBL] [Abstract][Full Text] [Related]
23. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia.
Guidez F; Ivins S; Zhu J; Söderström M; Waxman S; Zelent A
Blood; 1998 Apr; 91(8):2634-42. PubMed ID: 9531570
[TBL] [Abstract][Full Text] [Related]
24. Down-stream regions of the POZ-domain influence the interaction of the t(11;17)-associated PLZF/RARalpha fusion protein with the histone-deacetylase recruiting co-repressor complex.
Puccetti E; Sennewald B; Fosca-Ferrara F; Boehrer S; Bianchini A; Hoelzer D; Ottmann OG; Nervi C; Ruthardt M
Hematol J; 2001; 2(6):385-92. PubMed ID: 11920278
[TBL] [Abstract][Full Text] [Related]
25. The integrity of the charged pocket in the BTB/POZ domain is essential for the phenotype induced by the leukemia-associated t(11;17) fusion protein PLZF/RARalpha.
Puccetti E; Zheng X; Brambilla D; Seshire A; Beissert T; Boehrer S; Nürnberger H; Hoelzer D; Ottmann OG; Nervi C; Ruthardt M
Cancer Res; 2005 Jul; 65(14):6080-8. PubMed ID: 16024608
[TBL] [Abstract][Full Text] [Related]
26. [Acute promyelocytic leukemia, histone deacetylase, and response to retinoids].
Jeanteur P
Bull Cancer; 1998 Apr; 85(4):301-3. PubMed ID: 9752292
[TBL] [Abstract][Full Text] [Related]
27. Acute promyelocytic leukemia with a PLZF-RARalpha fusion protein.
Jansen JH; Löwenberg B
Semin Hematol; 2001 Jan; 38(1):37-41. PubMed ID: 11172538
[TBL] [Abstract][Full Text] [Related]
28. Modeling acute promyelocytic leukemia in the mouse: new insights in the pathogenesis of human leukemias.
Merghoub T; Gurrieri C; Piazza F; Pandolfi PP
Blood Cells Mol Dis; 2001; 27(1):231-48. PubMed ID: 11358384
[TBL] [Abstract][Full Text] [Related]
29. Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission.
Zhu J; Lallemand-Breitenbach V; de Thé H
Oncogene; 2001 Oct; 20(49):7257-65. PubMed ID: 11704854
[TBL] [Abstract][Full Text] [Related]
30. In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications.
He LZ; Merghoub T; Pandolfi PP
Oncogene; 1999 Sep; 18(38):5278-92. PubMed ID: 10498880
[TBL] [Abstract][Full Text] [Related]
31. Retinoic acid receptors, hematopoiesis and leukemogenesis.
Collins SJ
Curr Opin Hematol; 2008 Jul; 15(4):346-51. PubMed ID: 18536573
[TBL] [Abstract][Full Text] [Related]
32. Analysis of the modulation of transcriptional activity in myelopoiesis and leukemogenesis.
Behre G; Zhang P; Zhang DE; Tenen DG
Methods; 1999 Mar; 17(3):231-7. PubMed ID: 10080908
[TBL] [Abstract][Full Text] [Related]
33. Role of histone deacetylases in acute leukemia.
Fenrick R; Hiebert SW
J Cell Biochem Suppl; 1998; 30-31():194-202. PubMed ID: 9893271
[TBL] [Abstract][Full Text] [Related]
34. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias?
Minucci S; Nervi C; Lo Coco F; Pelicci PG
Oncogene; 2001 May; 20(24):3110-5. PubMed ID: 11420727
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic gene silencing in acute promyelocytic leukemia.
Villa R; De Santis F; Gutierrez A; Minucci S; Pelicci PG; Di Croce L
Biochem Pharmacol; 2004 Sep; 68(6):1247-54. PubMed ID: 15313423
[TBL] [Abstract][Full Text] [Related]
36. Analysis of the molecular genetics of acute promyelocytic leukemia in mouse models.
Rego EM; Pandolfi PP
Semin Hematol; 2001 Jan; 38(1):54-70. PubMed ID: 11172540
[TBL] [Abstract][Full Text] [Related]
37. The role of E2A-PBX1 in leukemogenesis.
Aspland SE; Bendall HH; Murre C
Oncogene; 2001 Sep; 20(40):5708-17. PubMed ID: 11607820
[No Abstract] [Full Text] [Related]
38. Dimerization: a versatile switch for oncogenesis.
So CW; Cleary ML
Blood; 2004 Aug; 104(4):919-22. PubMed ID: 15130940
[TBL] [Abstract][Full Text] [Related]
39. MOZ and MORF, two large MYSTic HATs in normal and cancer stem cells.
Yang XJ; Ullah M
Oncogene; 2007 Aug; 26(37):5408-19. PubMed ID: 17694082
[TBL] [Abstract][Full Text] [Related]
40. Leukemia-associated fusion proteins. Multiple mechanisms of action to drive cell transformation.
Insinga A; Pelicci PG; Inucci S
Cell Cycle; 2005 Jan; 4(1):67-9. PubMed ID: 15611639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
